Importer of Controlled Substances Registration, 37113 [2017-16698]
Download as PDF
<![CDATA[
37113
Federal Register / Vol. 82, No. 151 / Tuesday, August 8, 2017 / Notices
information. Any person that is neither
a party to the five-year review nor an
interested party may submit a brief
written statement (which shall not
contain any new factual information)
pertinent to the review by August 8,
2017. However, should the Department
of Commerce extend the time limit for
its completion of the final results of its
review, the deadline for comments
(which may not contain new factual
information) on Commerce’s final
results is three business days after the
issuance of Commerce’s results. If
comments contain business proprietary
information (BPI), they must conform
with the requirements of sections 201.6,
207.3, and 207.7 of the Commission’s
rules. The Commission’s rules with
respect to filing were revised effective
July 25, 2014. See 79 FR 35920 (June 25,
2014), and the revised Commission
Handbook on E-filing, available from the
Commission’s Web site at https://
edis.usitc.gov.
In accordance with sections 201.16(c)
and 207.3 of the rules, each document
filed by a party to the review must be
served on all other parties to the review
(as identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Determination.—The Commission has
determined this review is
extraordinarily complicated and
therefore has determined to exercise its
authority to extend the review period by
up to 90 days pursuant to 19 U.S.C.
1675(c)(5)(B).
Authority: This review is being
conducted under authority of title VII of
the Tariff Act of 1930; this notice is
published pursuant to section 207.62 of
the Commission’s rules.
By order of the Commission.
Issued: August 3, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017–16677 Filed 8–7–17; 8:45 am]
BILLING CODE 7020–02–P
Company
asabaliauskas on DSKBBXCHB2PROD with NOTICES
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrants to import the
applicable basic classes of schedule I or
II controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substances to
the above listed persons.
[FR Doc. 2017–16698 Filed 8–7–17; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
21:16 Aug 07, 2017
Jkt 241001
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
Notice of registration.
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as importers of
various classes of schedule I or II
controlled substances.
SUMMARY:
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
FR docket
Cambridge Isotope Laboratories ...............................................
Janssen Ortho LLC ....................................................................
Galephar Pharmaceutical Research, Inc. ..................................
Mallinckrodt LLC ........................................................................
Cerilliant Corporation .................................................................
Dated: August 2, 2017.
Demetra Ashley,
Acting Assistant Administrator.
DEPARTMENT OF JUSTICE
82
82
82
82
82
FR
FR
FR
FR
FR
19083
19083
23069
23071
25335
............................................................................
............................................................................
............................................................................
............................................................................
............................................................................
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Leia A. Frickey, M.D.; Decision and
Order
On February 28, 2017, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration (DEA), issued an Order
to Show Cause to Leia A. Frickey, M.D.
(Registrant), of New Orleans, Louisiana.
The Show Cause Order proposed the
revocation of Registrant’s Certificate of
Registration, the denial of any
applications to renew or modify her
registration, and the denial of any
applications for any other DEA
registration on the ground that she lacks
‘‘state authority to handle controlled
substances’’ in Louisiana, the State in
which she is registered with the DEA.
Order to Show Cause, at 1 (citing 21
U.S.C. 824(a)(3)).
With respect to the Agency’s
jurisdiction, the Show Cause Order
alleged that Registrant is registered as a
practitioner in schedules II through V,
pursuant to DEA Certificate of
Registration BF5029574, at the address
of 3312 South I–10 Service Road,
Metairie, Louisiana. Id. The Order also
PO 00000
Frm 00074
Fmt 4703
Published
Sfmt 4703
April 25, 2017.
April 25, 2017.
May 19, 2017.
May 19, 2017.
June 1, 2017.
alleged that this registration does not
expire until September 30, 2017. Id.
As substantive grounds for the
proceeding, the Show Cause Order
alleged that on May 6, 2016, the
Louisiana State Board of Medical
Examiners issued a ‘‘Notice of Summary
Suspension of Medical License,
summarily suspending [Registrant’s]
medical license.’’ 1 Id. at 1. As a result,
the Order alleged that Registrant is
‘‘currently without authority to practice
medicine or handle controlled
substances in . . . Louisiana, the [S]tate
in which [she is] registered with the
DEA.’’ Id. at 2. Thus, based on her ‘‘lack
of authority to [dispense] controlled
substances in . . . Louisiana,’’ the Order
asserted that ‘‘DEA must revoke’’ her
1 The Show Cause Order also alleges that ‘‘on July
25, 2016, the Louisiana Board of Pharmacy issued
a Notice of Suspension, suspending [Registrant’s]
Louisiana CDS license, number CDS.024813–MD,
effective May 6, 2016.’’ Id. at 1–2. Although those
exact facts are not reflected in the record, the record
does show that on November 16, 2016, the
Louisiana State Board of Pharmacy issued an Order
that Registrant’s ‘‘LOUISIANA CONTROLLED
SUBSTANCE LICENSE No. 024813 is hereby
indefinitely suspended in accordance with the
suspension of her medical license by the Louisiana
State Board of Medical Examiners on May 6, 2016.’’
See Government Exhibit (GX) 4, at 1.
E:\FR\FM\08AUN1.SGM
08AUN1
]]>Agencies
[Federal Register Volume 82, Number 151 (Tuesday, August 8, 2017)]
[Notices]
[Page 37113]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16698]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Registration
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Registrants listed below have applied for and been granted
registration by the Drug Enforcement Administration (DEA) as importers
of various classes of schedule I or II controlled substances.
SUPPLEMENTARY INFORMATION: The companies listed below applied to be
registered as importers of various basic classes of controlled
substances. Information on previously published notices is listed in
the table below. No comments or objections were submitted and no
requests for hearing were submitted for these notices.
------------------------------------------------------------------------
Company FR docket Published
------------------------------------------------------------------------
Cambridge Isotope 82 FR 19083......... April 25, 2017.
Laboratories.
Janssen Ortho LLC........... 82 FR 19083......... April 25, 2017.
Galephar Pharmaceutical 82 FR 23069......... May 19, 2017.
Research, Inc..
Mallinckrodt LLC............ 82 FR 23071......... May 19, 2017.
Cerilliant Corporation...... 82 FR 25335......... June 1, 2017.
------------------------------------------------------------------------
The DEA has considered the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the registration of the listed registrants
to import the applicable basic classes of schedule I or II controlled
substances is consistent with the public interest and with United
States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971. The DEA investigated each company's
maintenance of effective controls against diversion by inspecting and
testing each company's physical security systems, verifying each
company's compliance with state and local laws, and reviewing each
company's background and history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the DEA has granted a registration as
an importer for schedule I or II controlled substances to the above
listed persons.
Dated: August 2, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-16698 Filed 8-7-17; 8:45 am]
BILLING CODE 4410-09-P
